60 search results for: mechanism of disease

Can advanced systemic therapies modify patho<b>mechanism</b>s in AD?
expert video

Can advanced systemic therapies modify pathomechanisms in AD?

Dermatology
Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.
View more
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin <b>disease</b> (AD, PN, CSU)?
expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

Dermatology
Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.
View more
UCARE 2023: Role <b>of</b> Type 2 Inflammation in CSU Pathogenesis 
expert video

UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

Dermatology
Dr. Saini provides a deep dive into the pathophysiology of type 2 inflammation in CSU.
View more
The Role <b>of</b> Type 2 Inflammation in Atopic Dermatitis
expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

Dermatology
The impact of type 2 inflammation and barrier dysfunction in the pathogenesis of chronic disease in atopic dermatitis.
View more
Under the Itchy Surface: The Insidious, Cumulative Burden <b>of</b> Type 2 Inflammation in AD
expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Dermatology
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
View more
Unique Characteristics <b>of</b> Itch in AD, PN, and CSU – A Panel Discussion
expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

Dermatology
Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.
View more
Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients
expert video

Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients

Dermatology
Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.
View more
ADVENT On Air - Dermatology
Podcast

ADVENT On Air | Expert Discussions in Dermatology

Dermatology
Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.

View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
The Impact <b>of</b> Skin Fibrosis in Patients with Prurigo Nodularis
videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

Dermatology
An animated infographic exploring the patient burden and pathophysiology of skin fibrosis in prurigo nodularis, specifically detailing how fibrotic pathways are driven and the key molecules involved.
View more
The Role <b>of</b> Chronic Inflammation in the Pathogenesis <b>of</b> CSU
expert video

The Role of Chronic Inflammation in the Pathogenesis of CSU

Dermatology
Drs. Kim and Saini discuss the role of chronic inflammation in the pathogenesis of CSU in this insightful interview.
View more
A brief overview <b>of</b> the pathophysiology <b>of</b> PN
expert video

A brief overview of the pathophysiology of PN

Dermatology
Dr. Chovatiya explains that PN is primarily a chronic itch disease with a complex pathophysiology involving neuronal changes, type 2 inflammation, and fibrotic skin processes, affecting patients' overall well-being.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FranceChange country/region